

1 **Supplementary information**

2

3 **High-Throughput Screen with the L,D-transpeptidase Ldt_{Mt2} of *Mycobacterium tuberculosis***
4 **Reveals Novel Classes of Covalent Inhibitors**


5 Mariska de Munnik¹, Pauline A. Lang¹, Francisco De Dios Anton², Monica Cacho², Robert Bates², Jürgen
6 Brem^{1,3}, Beatriz Rodríguez Miquel^{2*} and Christopher J. Schofield^{1*}


7 ¹ Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute of
8 Antimicrobial Research, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, United Kingdom.

9 ² Tres Cantos Medicines Development Campus GlaxoSmithKline, Calle Severo Ochoa 2, Tres Cantos,
10 Madrid, Spain.

11 ³ Present address: Janssen Research & Development, Janssen Pharmaceutica, B-2340 Beerse, Belgium.

12 * Email: beatriz.rodriguez@gsk.com and christopher.schofield@chem.ox.ac.uk





17

18 **Figure S2. Optimisation of the HTS assay for Ldt_{Mt2}.** (A) Z' values obtained with varying concentrations
 19 of Ldt_{Mt2} at a fixed probe **1** concentration (20 μM). The Z' values were ≥ 0.8 for Ldt_{Mt2} concentrations ≥
 20 300 nM. (B) Z' values obtained with varying concentrations of probe **1** at a fixed Ldt_{Mt2} concentration
 21 (300 nM). The optimal Z' value (0.87) was obtained with probe **1** at 15 μM. (C) Z' values obtained with
 22 varying reaction volumes, using fixed Ldt_{Mt2} (300 nM) and probe **1** (15 μM) concentrations. A lower
 23 reaction volume decreased the Z' value, but up to a volume of 10 μL, the Z' values are sufficiently high
 24 (≥ 0.40). (D) Optimisation of the plate reader settings improved the Z' values of the assay. The
 25 optimisation protocol included exchanging the general dual mirror to a FITC mirror increases the Z'
 26 value from 0.82 to 0.95. Optimising the plate reader protocol in terms of coordinates of corners,
 27 measurement height and gain further improved the Z' value to 0.97. (E) Time-course of the relative
 28 fluorescence units (RFU) measured on reaction of probe **1** (15 μM) with (300 nM, black) and without
 29 (teal) Ldt_{Mt2} at room temperature in (error bars; SD, n=32). The reaction between probe **1** and Ldt_{Mt2}
 30 was shown to reach completion after 5 hours, with the initial linear phase lasting 1 hour. (F) DMSO
 31 interference assay. Assays were performed at varied DMSO concentrations (error bars; SD, n=4). Up to
 32 a concentration of 3% (v/v) DMSO did not affect the assay. Assays were carried out with 300 nM Ldt_{Mt2}
 33 and 15 μM probe **1** at room temperature. Assays were carried out at room temperature in 50 mM
 34 sodium phosphate pH 7.5 with 0.01% (v/v) Triton X-100. Assays in (A) and (B) used reaction volumes
 35 of 25 μL. Assays in (D) - (F) used reaction volumes of 10 μL.

36

37 **Table S1. Influence of detergents on Z' and signal to background ratio (S/B).** The reaction between
 38 Ldt_{Mt2} (300 nM) and probe 1 (15 μM) was monitored at room temperature in 50 mM sodium phosphate
 39 pH 7.5 in the presence of the indicated detergents. The maximum tolerated concentrations of each
 40 detergent were determined in interference assays at varying detergent concentrations and were
 41 defined as the highest tested concentration at which no interference was observed.


Detergent	Maximum tolerated concentration (v/v)	Z'	S/B
Triton X-100	0.03%	0.77	2.5
Triton X-114	0.02%	0.77	2.3
Tween-20	0.007%	0.82	3.2
Tween-80	0.001%	0.66	2.2
MEGA-8	1.25%	0.77	3.3
CHAPS	0.245%	0.76	2.8
BRIJ-35	0.000054%	N.D.	N.D.
IPEGAL-630	0.00028%	N.D.	N.D.
DDM	0.00014%	N.D.	N.D.
BSA	<0.00064%	N.D.	N.D.
dBSA	<0.00064%	N.D.	N.D.

42

43 **Table S2. Stability analysis of Ldt_{Mt2} and probe 1 stock solutions.** The stabilities of stock solutions of
44 Ldt_{Mt2} and probe 1 were assessed by comparing the Z' and signal to background ratios (S/B) of the
45 assay using fresh and aged (7 h, on ice) stock solutions. The results show very similar Z' and S/B values.
46 Assays were carried out with 300 nM Ldt_{Mt2} and 15 μM probe 1 at room temperature in 50 mM sodium
47 phosphate pH 7.5 with 0.007% (v/v) Tween-20.

	Z'	S/B
Fresh stocks	0.97	14.5
7 hours old stocks	0.96	14.4

48













49







50 **Figure S3. Analysis of a 384-well plate to test for variance in plate patterns.** The full plate analysis
 51 using final assay conditions (300 nM Ldt_{Mt2} and 15 μM probe 1 at room temperature in 50 mM sodium
 52 phosphate pH 7.5 with 0.007% (v/v) Tween-20) shows no evidence for non-specific patterns across the
 53 assay plate, as measured 1 h after start of the reaction. Column 18 represents the no enzyme control.

54


55 **Table S3. Dose-response analysis results for tool compounds.** Compounds were incubated with Ldt_{MT2}
 56 or BlaC (10 min.), then assayed using the optimised assay conditions (see Experimental Details).
 57 Inhibition assays of Ldt_{MT2} were carried out with 300 nM Ldt_{MT2} and 15 μM probe **1** at room temperature
 58 in 50 mM sodium phosphate pH 7.5 with 0.007% (v/v) Tween-20. Inhibition assays of BlaC were carried
 59 out with 2.5 nM BlaC and 2.5 μM FC5 at room temperature in 100 mM sodium phosphate pH 7.5 with
 60 0.01% (v/v) Triton X-100. pIC₅₀s were determined via non-linear regression in Graphpad Prism. (n=4,
 61 mean ± SD)

Compound	Structure	pIC ₅₀ Ldt _{MT2} (mean ± SD)	pIC ₅₀ BlaC (mean ± SD)
Faropenem		6.5 ± 0.04	6.35 ± 0.03
Sulopenem		6.2 ± 0.03	6.60 ± 0.12
Panipenem		6.5 ± 0.05	6.78 ± 0.01
Ertapenem		5.8 ± 0.08	6.75 ± 0.03
Doripenem		5.3 ± 0.16	7.38 ± 0.04
Meropenem		5.0 ± 0.11	6.85 ± 0.05
Biapenem		4.1 ± 0.03	5.51 ± 0.09
Flucloxacillin		4.6 ± 0.09	6.87 ± 0.03

Compound	Structure	pIC ₅₀ Ldt _{Mt2} (mean ± SD)	pIC ₅₀ BlaC (mean ± SD)
Oxacillin		4.2 ± 0.03	6.80 ± 0.01
Ticarcillin		<4.0	4.93 ± 0.01
Carbenicillin		<4.0	<4.0
Sulbactam		<4.0	5.12 ± 0.01
Zidebactam		4.0 ± 0.02	4.15 ± 0.10
Relebactam		<4.0	4.48 ± 0.01
Ceftazidime		<4.0	4.40 ± 0.01
Cefminox		<4.0	4.50 ± 0.01
Cefotaxime		<4.0	<4.0
Ceftiofur		<4.0	<4.0


Compound	Structure	pIC ₅₀ Ldt _{MT2} (mean ± SD)	pIC ₅₀ BlaC (mean ± SD)
Iodoacetamide		5.8 ± 0.03	<4.0
Maleimide		5.4 ± 0.04	<4.0
Ebselen		6.8 ± 0.03	5.82 ± 0.09
Benzeneseleninic acid		5.0 ± 0.06	<4.0
Thiram		6.8 ± 0.03	<4.0
PX-12		5.9 ± 0.01	<4.0

62



63


64 **Figure S4. Optimisation of the HTS assay for BlaC.** (A) Z' values obtained with varying concentrations
 65 of BlaC using a fixed concentration of probe FC5² (10 μM). (B) Z' values obtained with varying
 66 concentrations of FC5 using a fixed BlaC concentration (2.5 nM). A Z' value of 0.95 was obtained at a
 67 FC5 concentration of 2.5 μM. (C) Z' values obtained with varying reaction volumes using fixed BlaC and
 68 FC5 concentrations (2.5 nM and 2.5 μM, respectively). Assays in (A) and (B) used reaction volumes of
 69 25 μL. Assays were performed at room temperature in 100 mM sodium phosphate pH 7.5 with 0.01%
 70 (v/v) Triton X-100.



71

72 **Figure S5. Z' values of the plates throughout the HTS campaign. (A)** Z' values for the Ldt_{M12} HTS assay.
73 **(B)** Z' values for the HTS assay for the BlaC HTS assay. The cut-off value for plate acceptance is indicated
74 at Z' > 0.4.

75













76







77 **Figure S6. Dose response assay results of tool compounds as HTS validation.** pIC₅₀ values for Ldt_{Mt2}
 78 inhibition **(A)** and BlaC inhibition **(B)** were measured on different days, and show good reproducibility
 79 for the tested compounds. Inhibition assays of Ldt_{Mt2} were carried out with 300 nM Ldt_{Mt2} and 15 μM
 80 probe **1** with 30 minutes inhibitor pre-incubation at room temperature in 50 mM sodium phosphate
 81 pH 7.5 with 0.007% (v/v) Tween-20. Inhibition assays of BlaC were carried out with 2.5 nM BlaC and
 82 2.5 μM FC5 with 30 minutes inhibitor pre-incubation at room temperature in 100 mM sodium
 83 phosphate pH 7.5 with 0.01% (v/v) Triton X-100. Average pIC₅₀ values and compound structures are
 84 given in Table S4.

85


86 **Table S4. Validation of the HTS assay using tool compounds.** pIC_{50} values for Ldt_{Mt2} and BlaC inhibition,
 87 as obtained from independent repeats of technical duplicates during the HTS validation. Errors given
 88 are SD of the independent repeats (Ldt_{Mt2} assay $n=6$, BlaC assay $n=8$). Inhibition assays of Ldt_{Mt2} were
 89 carried out with 300 nM Ldt_{Mt2} and 15 μ M probe **1** with 30 minutes inhibitor pre-incubation at room
 90 temperature in 50 mM sodium phosphate pH 7.5 with 0.007% (v/v) Tween-20. Inhibition assays of BlaC
 91 were carried out with 2.5 nM BlaC and 2.5 μ M FC5 with 30 minutes inhibitor pre-incubation at room
 92 temperature in 100 mM sodium phosphate pH 7.5 with 0.01% (v/v) Triton X-100.

Compound	Structure	pIC_{50} Ldt_{Mt2} (mean \pm SD)	pIC_{50} BlaC (mean \pm SD)
Faropenem		6.39 \pm 0.03	6.33 \pm 0.06
Sulopenem		6.35 \pm 0.02	6.86 \pm 0.02
Panipenem		5.91 \pm 0.02	7.03 \pm 0.06
Ertapenem		6.11 \pm 0.04	7.17 \pm 0.03
Doripenem		5.77 \pm 0.04	7.85 \pm 0.02
Meropenem		5.87 \pm 0.04	7.39 \pm 0.03
Biapenem		5.54 \pm 0.07	6.32 \pm 0.11
Flucloxacillin		5.98 \pm 0.06	7.11 \pm 0.07

Compound	Structure	pIC ₅₀ Ldt _{Mt2} (mean ± SD)	pIC ₅₀ BlaC (mean ± SD)
Oxacillin		5.22 ± 0.06	7.17 ± 0.03
Ticarcillin		4.35 ± 0.02	4.84 ± 0.06
Carbenicillin		<4.0	<4.0
Sulbactam		<4.0	5.02 ± 0.03
Zidebactam		4.88 ± 0.02	5.14 ± 0.10
Relebactam		<4.0	5.40 ± 0.04
Ceftazidime		<4.0	4.92 ± 0.07
Cefminox		<4.0	4.66 ± 0.08
Cefotaxime		<4.0	<4.0
Ceftiofur		<4.0	<4.0

Compound	Structure	pIC ₅₀ Ldt _{MT2} (mean ± SD)	pIC ₅₀ BlaC (mean ± SD)
Iodoacetamide		6.05 ± 0.03	<4.0
Maleimide		5.65 ± 0.04	<4.0
Ebselen		6.67 ± 0.04	6.52 ± 0.04
Benzeneseleninic acid		5.45 ± 0.05	<4.0
Thiram		6.77 ± 0.02	<4.0
PX-12		6.09 ± 0.03	<4.0

93























94












95 **Figure S7. Correlation between pIC₅₀ values from two independent repeats in the HTS. (A)** for Ldt_{Mt2}
 96 and **(B)** for BlaC of the two independent repeats using the standard assay conditions (Figure S2E, Figure
 97 S4C).








98


99 **Table S5. Eight classes of compounds identified from the Ldt_{Mt2} HTS.** MW: Molecular weight. LE:
 100 Ligand efficiency. T_m: Melting point (°C) of Ldt_{Mt2} after pre-incubation with the compound as measured
 101 using SYPRO Orange (6 x concentrated, according to the manufacturer's (Invitrogen) protocol) in 50
 102 mM Tris pH 7.5. ΔT_m: Difference in melting point (T_m) of Ldt_{Mt2} after pre-incubation with the compound
 103 relative to unreacted Ldt_{Mt2} (43.8 °C). k_{chem}: apparent intrinsic thiol reactivity as measured with L-
 104 glutathione and probe **2** (Figure S20).

Class	Compound	MW (Da)	pIC ₅₀		LE	T _m (ΔT _m)	k _{inact} /K _i (M ⁻¹ s ⁻¹)	k _{chem} (M ⁻¹ s ⁻¹)
			Ldt _{Mt2}	BlaC				
α-chloro ketone		382.85	7.34 ± 0.045	<4.0	0.41	N.D.	1152 ± 87	0.11 ± 0.02
		297.78	7.11 ± 0.010	<4.0	0.56	43.7 ± 0.09 (-0.1)	68.4 ± 3.5	0.15 ± 0.02
Maleimides		173.17	7.15 ± 0.030	5.03 ± 0.045	0.86	45.0 ± 0.16 (+1.2)	3991 ± 356	129.9 ± 9.9
		269.25	7.06 ± 0.035	4.22 ± 0.060	0.62	45.6 ± 0.28 (+1.8)	36.5 ± 7.9	34.2 ± 1.0
		299.71	7.40 ± 0.010	4.71 ± 0.055	0.53	43.6 ± 0.16 (-0.2)	116 ± 6.2	91.8 ± 1.8
		288.30	7.24 ± 0.005	5.19 ± 0.005	0.52	45.5 ± 0.09 (+1.7)	127 ± 7.7	61.6 ± 0.78
		231.21	7.02 ± 0.000	4.18 ± 0.175	0.66	43.1 ± 0.09 (-0.7)	156 ± 5.1	91.7 ± 4.5
		435.71	7.16 ± 0.035	<4.0	0.43	44.5 ± 1.23 (+0.7)	91.6 ± 2.0	1.53 ± 0.15
		306.34	6.68 ± 0.025	4.58 ± 0.010	0.53	43.1 ± 0.09 (-0.7)	90.7 ± 4.7	1.76 ± 0.20
Acrylamides		282.30	6.37 ± 0.005	4.29 ± 0.290	0.54	44.5 ± 0.19 (-0.7)	16.0 ± 0.75	0.79 ± 0.02

Class	Compound	MW (Da)	pIC ₅₀		LE	T _m (ΔT _m)	k _{inact} /K _i (M ⁻¹ s ⁻¹)	k _{chem} (M ⁻¹ s ⁻¹)
			Ldt _{Mt2}	BlaC				
Acrylamides (continued)		270.29	6.24 ± 0.030	<4.0	0.56	44.0 ± 0.16 (+0.2)	172 ± 6.0	0.27 ± 0.05
		268.27	6.13 ± 0.115	<4.0	0.56	44.1 ± 0.09 (+0.3)	N.D.	0.55 ± 0.11
Fumaryl-amides		224.65	6.38 ± 0.080	<4.0	0.75	44.8 ± 0.00 (+1.0)	6.48 ± 0.11	6.1 ± 0.52
		204.23	6.11 ± 0.020	<4.0	0.75	44.9 ± 0.09 (+1.1)	1.20 ± 0.15	13.0 ± 1.0
Ebsulfur analogue		264.13	7.99 ± 0.040	6.37 ± 0.175	0.74	43.5 ± 0.09 (-0.3)	N.D.	N.D.
Isatins		404.26	6.75 ± 0.015	4.44 ± 0.015	0.45	46.8 ± 0.00 (+3.0)	N.D.	<0.08
		390.23	6.24 ± 0.140	<4.0	0.47	46.8 ± 0.00 (+3.0)	N.D.	<0.08
		366.21	6.52 ± 0.005	<4.0	0.49	46.2 ± 0.00 (+2.4)	N.D.	<0.08
β-Lactams		477.52	5.62 ± 0.100	<4.0	0.35	42.9 ± 0.09 (-0.9)	N.D.	N.D.
		625.66	5.55 ± 0.045	7.72 ± 0.015	0.28	42.7 ± 0.25 (-1.1)	N.D.	N.D.


Class	Compound	MW (Da)	pIC ₅₀		LE	T _m (ΔT _m)	k _{inact} /K _i (M ⁻¹ s ⁻¹)	k _{chem} (M ⁻¹ s ⁻¹)	
			Ldt _{Mt2}	BlaC					
β-Lactams (continued)		432.29	6.40 ± 0.035	4.58 ± 0.195	0.45	43.1 ± 0.09 (-0.7)	53.2 ± 4.7	2.03 ± 0.76	
		305.23	7.53 ± 0.010	<4.0	0.51	42.5 ± 0.09 (-1.3)	55.1 ± 3.0	20.3 ± 0.9	
		305.23	7.33 ± 0.065	<4.0	0.51	42.5 ± 0.09 (-1.3)	265 ± 17	15.0 ± 0.41	
		221.22	7.34 ± 0.030	<4.0	0.66	42.0 ± 0.00 (-1.8)	158 ± 5.7	27.1 ± 2.3	
		221.22	7.34 ± 0.050	<4.0	0.66	42.4 ± 0.00 (-1.8)	77.5 ± 6.0	28.7 ± 1.9	
		271.28	7.45 ± 0.015	4.83 ± 0.110	0.53	41.7 ± 0.09 (-2.1)	65.0 ± 4.4	11.4 ± 0.62	
	Nitriles		244.32	7.02 ± 0.025	<4.0	0.66	42.5 ± 0.09 (-1.3)	14.0 ± 0.73	6.50 ± 0.25
			228.25	6.39 ± 0.120	<4.0	0.66	42.3 ± 0.09 (-1.5)	7.41 ± 0.40	2.12 ± 0.15
		302.36	7.28 ± 0.010	6.18 ± 0.040	0.51	42.9 ± 0.19 (-0.9)	1164 ± 105	42.1 ± 0.82	
		316.39	7.25 ± 0.065	6.11 ± 0.150	0.49	42.2 ± 0.00 (-1.6)	236 ± 9.5	N.D.	
		303.35	7.32 ± 0.055	4.95 ± 0.070	0.51	42.1 ± 0.10 (-1.7)	609 ± 11	21.0 ± 1.4	
		319.36	7.31 ± 0.045	4.73 ± 0.080	0.47	42.3 ± 0.09 (-1.5)	86.3 ± 2.6	3.58 ± 0.19	

Class	Compound	MW (Da)	pIC ₅₀		LE	T _m (ΔT _m)	k _{inact} /K _i (M ⁻¹ s ⁻¹)	k _{chem} (M ⁻¹ s ⁻¹)
			Ldt _{Mt2}	BlaC				
Nitriles (continued)		286.29	6.95 ± 0.045	6.09 ± 0.125	0.51	43.3 ± 0.09 (-0.5)	71.8 ± 1.1	12.9 ± 0.67
		297.32	7.20 ± 0.080	<4.0	0.49	42.1 ± 0.09 (-1.7)	68.4 ± 2.7	31.0 ± 1.6
		297.32	7.01 ± 0.015	5.91 ± 0.385	0.49	42.9 ± 0.34 (-0.9)	8.88 ± 0.39	16.8 ± 0.61
		324.34	7.11 ± 0.050	<4.0	0.45	40.8 ± 0.59 (-3.0)	51.0 ± 3.4	61.6 ± 2.7
		300.14	6.43 ± 0.025	4.47 ± 0.075	0.59	42.3 ± 0.09 (-1.5)	8.44 ± 1.2	0.30 ± 0.03
		341.46	6.15 ± 0.010	<4.0	0.45	42.8 ± 0.00 (-1.0)	N.D.	N.D.
		327.43	6.29 ± 0.065	<4.0	0.47	43.1 ± 0.10 (-0.7)	N.D.	N.D.




105

106 **Figure S8. Dose-response curves for compounds 1-39 with Ldt_{M12} (figure continues).**




107

108 **Figure S8. Dose-response curves for compounds 1-39 with Ldt_{M12} (figure continues).**




109

110 **Figure S8. Dose-response curves for compounds 1-39 with Ldt_{Mt2}.** Inhibition assays of Ldt_{Mt2} were
 111 carried out with 300 nM Ldt_{Mt2} and 15 μ M probe **1** with a 30 minute inhibitor pre-incubation at room
 112 temperature in 50 mM sodium phosphate pH 7.5 with 0.007% (v/v) Tween-20. Two independent
 113 repeats are shown in teal and cyan. Average pIC₅₀ values and compound structures are given in Table
 114 S5.




115

116 **Figure S9. Dose-response curves for compounds 1-39 with BlaC (figure continues).**



117


118 **Figure S9. Dose-response curves for compounds 1-39 with BlaC (figure continues).**



119


120 **Figure S9. Dose-response curves for compounds 1-39 with BlaC.** Inhibition assays of BlaC were carried
 121 out with 2.5 nM BlaC and 2.5 μ M FC5 with a 30 minute inhibitor pre-incubation at room temperature
 122 in 100 mM sodium phosphate pH 7.5 with 0.01% (v/v) Triton X-100. Two independent repeats are
 123 shown in teal and cyan. Average pIC₅₀ values and compound structures are given in Table S5.

124




125

126 **Figure S10. Protein observed SPE-MS analysis for the reaction of Ldt_{M12} with inhibitors 1-21 (figure**
 127 **continues).**




128

129 **Figure S10. Protein observed SPE-MS analysis for the reaction of Ldt_{Mt2} with inhibitors 1-21 (figure**
 130 **continues).**




131

132 **Figure S10. Protein observed SPE-MS analysis for the reaction of Ldt_{M12} with inhibitors 1-21 (figure**
 133 **continues).**



134

135 **Figure S10. Protein observed SPE-MS analysis for the reaction of Ldt_{M12} with inhibitors 1-21 (figure**
 136 **continues).**



137


138 **Figure S10. Protein observed SPE-MS analysis for the reaction of Ldt_{Mt2} with inhibitors 1-21.** 1 μ M
 139 Ldt_{Mt2} was incubated with the inhibitors at the specified ratio at room temperature in 50 mM Tris, pH
 140 7.5. Samples were analysed after the indicated times. Compound structures are given in Table S5.
 141 Deconvoluted spectra, obtained using the maximum entropy algorithm in the MassHunter
 142 Workstation Qualitative Analysis B.07.00 program (Agilent), are shown.

143

144 **Table S6. Calculated (based on anticipated binding mode) and observed masses (Da) and mass shifts**
 145 **(Da) for protein observed SPE-MS experiments with Ldt_{Mt2} and the indicated inhibitors.** Mass shifts
 146 are relative to unmodified Ldt_{Mt2}. * Calculated mass for reaction at the inhibitor terminal amide group.
 147 ** Calculated mass for reaction at the inhibitor acrylamide group. Compound structures are given in
 148 Table S5. Deconvoluted SPE-MS spectra are shown in Figure S10.


Compound	Calculated mass (Da)	Observed mass (Da)
1	38334 (+347)	38334 (+347)
2	38249 (+262)	38249 (+262)
3	38161 (+174)	38161 (+174)
4	38257 (+270)	38257 (+270)
5	38287 (+300)	38287 (+300), 38303 (+316)
6	38276 (+289)	38276 (+289), 38582 (+595), 38889 (+902), 39196 (+1209)
7	38219 (+232)	38113 (+126), 38219 (+232), 38235 (+248)
8	38386 (+399)	38386 (+399)
9	38293 (+306)	38309 (+322), 38325 (+338)
10	38269 (+282)	38173 (+186), 38285 (+298)
11	38257 (+270)	38273 (+286), 38289 (+302)
12	38255 (+268)	38255 (+268)
13	38195 (+208)*, 38212 (+225)**	38195 (+208)
14	38175 (+188)*, 38191 (+204)**	38175 (+188)
15	38251 (+264)	38251 (+264)
16	38391 (+404)	38391 (+404)
17	38377 (+390)	38377 (+390), 38767 (+780)
18	38353 (+366)	37987 (+0)
19	38465 (+478)	38034 (+47), 38348 (+361)
20	38613 (+626)	38031 (+44), 38202 (+215), 38552 (+565), 38613 (+626)
21	38419 (+432)	38031 (+44), 38132 (+145), 38384 (+397), 38460 (+473), 38565 (+578)

149




150

151 **Figure S11. Protein observed SPE-MS based active-site selectivity assays (figure continues).**



152

153 **Figure S11. Protein observed SPE-MS based active-site selectivity assays.** Ldt_{Mt2} (1 μM) was
 154 preincubated with ebselen (10 μM, a known Ldt_{Mt2} inhibitor³, which reacts with the nucleophilic
 155 Cys354) for 1 h in 50 mM Tris, pH 7.5, prior to addition of inhibitors **1-15** (100 μM). Samples were
 156 analysed after an additional 24 h incubation at room temperature. The spectrum in blue corresponds
 157 to Ldt_{Mt2} reacted with ebselen. The spectrum in green corresponds to Ldt_{Mt2} reacted with the specified
 158 inhibitor, following preincubation with ebselen. The spectrum in purple corresponds to Ldt_{Mt2} reacted
 159 with the specified inhibitor. Deconvoluted spectra, obtained using the maximum entropy algorithm in
 160 the MassHunter Workstation Qualitative Analysis B.07.00 program (Agilent), are shown.



161
 162 **Figure S12. Characterisation of the inhibition of Ldt_{Mt2} by isatins 16-18.** **A.** Non-denaturing MS
 163 analyses of Ldt_{Mt2} reaction with isatins **16**, **17**, and **18**. Ldt_{Mt2} (5 μM) was combined with **16**, **17** or **18**
 164 (500 μM) in 500 mM ammonium acetate. Mass spectra were recorded at cone voltages ranging from
 165 40 V to 200 V. The mass shifts induced by inhibitor binding are shown for the +11 charge state (**16**) or
 166 the +10 charge state (**17** and **18**) and correspond to the binding of a single inhibitor molecule. **B.**
 167 Thermal shift assays with isatins **16-18**. Ldt_{Mt2} (5 μM) and the specified inhibitor (500 μM) were
 168 preincubated for 30 minutes prior to addition of SYPRO Orange (6 x concentrated, according to the
 169 manufacturer's (Invitrogen) protocol) in 50 mM Tris, pH 7.5. **C.** Jump dilution assays with isatins **16-18**.
 170 Ldt_{Mt2} (10 μM) and the specified inhibitor (100 μM) in 50 mM HEPES, pH 7.2, 0.01% (v/v) Triton X-100
 171 were incubated for 2 hours at room temperature, then 1000 x diluted and assayed with probe **2** (15
 172 μM). The results imply that binding of the tested isatin inhibitors is reversible. The *k*_{off} and *t*_{1/2} values
 173 are given in Table S7. **D.** Dose-response assays with isatins **16-18** at varying inhibitor pre-incubation
 174 times. Assays of Ldt_{Mt2} were carried out with 300 nM Ldt_{Mt2} and 15 μM probe **1** at room temperature
 175 in 50 mM sodium phosphate pH 7.5 with 0.007% (v/v) Tween-20. Average pIC₅₀ values are given in
 176 Table S8.

177

178 **Table S7. Off rate (k_{off}) and half-life ($t_{1/2}$) of isatins 16 – 18 in complex with Ldt_{ME2}, as determined by**
179 **jump dilution assays.**

Compound	k_{off} (s⁻¹)	$t_{1/2}$ (min)
16	103 ± 16.5	0.41 ± 0.17
17	84.6 ± 6.03	0.49 ± 0.094
18	160 ± 15.5	0.26 ± 0.17


180

181

182 **Table S8. Dose-response assays with isatins 16-18 at varying inhibitor pre-incubation times.**


Compound	pIC ₅₀			
	0 min	10 min	60 min	120 min
16	6.52 ± 0.06	6.44 ± 0.11	6.43 ± 0.32	6.39 ± 0.37
17	6.48 ± 0.14	6.33 ± 0.14	6.28 ± 0.45	6.45 ± 0.26
18	6.39 ± 0.07	6.24 ± 0.23	6.49 ± 0.35	6.56 ± 0.35

183




184

185 **Figure S13. Protein observed SPE-MS analysis for the reaction of Ldt_{M12} with inhibitors 22-39 (figure**
 186 **continues).**



187

188 **Figure S13. Protein observed SPE-MS analysis for the reaction of Ldt_{Mt2} with inhibitors 22-39 (figure**
 189 **continues).**




190

191 **Figure S13. Protein observed SPE-MS analysis for the reaction of Ldt_{Mt2} with inhibitors 22-39.** 1 μ M
 192 Ldt_{Mt2} was incubated with the inhibitor at the specified ratio at room temperature in 50 mM Tris, pH
 193 7.5. Samples were analysed after the indicated times. Compound structures are given in Table S5.
 194 Deconvoluted spectra, obtained using the maximum entropy algorithm in the MassHunter
 195 Workstation Qualitative Analysis B.07.00 program (Agilent), are shown.

196 **Table S9. Calculated* and observed masses (Da) and mass shifts (Da) from protein observed SPE-MS**
 197 **experiments with Ldt_{Mt2} (1 μM) and the indicated nitrile inhibitors.** Mass shifts are relative to
 198 unmodified Ldt_{Mt2}. *Calculated mass for cyanation of Ldt_{Mt2}. **Calculated mass for unfragmented
 199 adduct formation. ***Due to complexity of the obtained mass spectra, only major observed peaks are
 200 provided.



Compound	Calculated mass (Da)	Observed mass (Da)
22	38004 (+26)*, 38283 (+305)**	38004 (+26)
23	38004 (+26)*, 38283 (+305)**	38004 (+26)
24	38004 (+26)*, 38199 (+221)**	38004 (+26), 38030 (+52), 38224 (+246)
25	38004 (+26)*, 38199 (+221)**	38004 (+26)
26	38004 (+26)*, 38249 (+271)**	38004 (+26)
27	38004 (+26)*, 38222 (+244)**	38004 (+26)
28	38004 (+26)*, 38206 (+228)**	38004 (+26)
29	38004 (+26)*, 38280 (+302)**	38004 (+26), 38022 (+44)
30	38004 (+26)*, 38294 (+316)**	38004 (+26)
31	38004 (+26)*, 38281 (+303)**	38004 (+26)
32	38004 (+26)*, 38297 (+319)**	38004 (+26)
33	38004 (+26)*, 38264 (+286)**	38004 (+26), 38022 (+44), 38291 (+313)
34	38004 (+26)*, 38275 (+297)**	38004 (+26), 38030 (+52), 38056 (+78), 38301 (+323), 38327 (+349), 38353 (+375)
35	38004 (+26)*, 38275 (+297)**	38004 (+26), 38022 (+44)
36	38004 (+26)*, 38302 (+324)**	38004 (+26), 38022 (+44)
37	38004 (+26)*, 38278 (+300)**	38102 (+124), 38278 (+300), 38402 (+424), 38578 (+600)
38	38319 (+341)**	38024 (+46), 38277 (+299), 38293 (+315), 38331 (+353)***
39	38305 (+327)**	38024 (+46), 38125 (+147), 38157 (+179), 38252 (+274), 38277 (+299), 38296 (+318), 38316 (+338)***

201



202

203 **Figure S14. Protein observed SPE-MS based active-site selectivity assays with nitriles 22-36.** Ldt_{Mt2} (1
 204 μ M) was preincubated with ebselen (10 μ M, a known Ldt_{Mt2} inhibitor³, which reacts with the
 205 nucleophilic Cys354) for 1 h in 50 mM Tris, pH 7.5, prior to addition of inhibitors **22-36** (100 μ M).
 206 Samples were analysed after an additional 24 h incubation at room temperature. The spectrum in blue
 207 corresponds to Ldt_{Mt2} in complex with ebselen. The spectrum in green corresponds to Ldt_{Mt2} and the
 208 specified inhibitor upon preincubation with ebselen. The spectrum in purple corresponds to Ldt_{Mt2} in
 209 complex with the specified inhibitor. Deconvoluted spectra, obtained using the maximum entropy
 210 algorithm in the MassHunter Workstation Qualitative Analysis B.07.00 program (Agilent), are shown.









211

212 **Figure S15. pH dependence of the cyanation of Ldt_{Mt2} by representative cyanamides 22, 27, 31 and**
 213 **36. MS spectra were taken 15 min after addition of the nitrile (10 μ M) to Ldt_{Mt2} (1 μ M) in 50 mM Tris,**
 214 **pH 7.5. (A) Area of cyanated and unmodified Ldt_{Mt2} peaks at the specified pH. (B) MS spectra of Ldt_{Mt2}**
 215 **following reaction with selected cyanamides at the specified pH values.**


216

217 **Table S10. Inhibition of Ldt_{MT2} by known cyanating compounds.**^{4,5} MW: Molecular weight. *k*_{chem}:
 218 apparent intrinsic thiol reactivity as measured with *L*-glutathione and probe **2**.

	Structure	MW	pIC ₅₀ Ldt _{MT2}	<i>k</i> _{chem}
40		143.15	6.31 ± 0.03	0.90 ± 0.05
41		93.09	6.54 ± 0.01	3.69 ± 0.11
42		144.14	6.02 ± 0.05	0.90 ± 0.08
43 (CDAP)		234.99	5.30 ± 0.08	N.D.
44 (NTCB)		224.19	5.84 ± 0.04	N.D.
45 (CDTP)		359.34	<4.4	N.D.


219

220




221

222 **Figure S16. Protein observed SPE-MS analysis for the reaction of Ldt_{Mt2} with cyanating agents 40-45.**
 223 1 μM Ldt_{Mt2} was incubated with 100 μM cyanating agent at room temperature in 50 mM Tris, pH 7.5.
 224 Samples were analysed after the indicated times. Compound structures are given in Table S10.
 225 Deconvoluted spectra, obtained using the maximum entropy algorithm in the MassHunter
 226 Workstation Qualitative Analysis B.07.00 program (Agilent), are shown.




227

228 **Figure S17. Protein observed SPE-MS analysis of the reaction of Ldt_{Mt2} with 22 (a representative of**
 229 **cyanamides 22-36) and 40-45, showing evidence for cleavage of Ldt_{Mt2} at Cys354 after prolonged**
 230 **incubation for 22 and 40-44.** 1 μM Ldt_{Mt2} was incubated with the inhibitor at a 1 to 100 ratio at room
 231 temperature in 50 mM Tris, pH 7.5. Samples were analysed after the indicated times. Compound
 232 structures are given in Table S5 and Table S9. Deconvoluted spectra, obtained using the maximum
 233 entropy algorithm in the MassHunter Workstation Qualitative Analysis B.07.00 program (Agilent), are
 234 shown. Note, cleavage was not observed in the case of compound 45.




235

236 **Figure S18. Assay set up for the determination of the second-order rate constant k_{inact}/K_i for**
 237 **irreversible inactivation of Ldt_{Mt2} via an endpoint assay using irreversibly reacting Probe 2. A.**
 238 **Determination of the observed kinetic rate constant (k_{obs}). Assays were carried out using 100 nM Ldt_{Mt2}**
 239 **at room temperature in 50 mM HEPES, pH 7.2 with 0.01% (v/v) Triton X-100, using varying Probe 2**
 240 **concentrations, as specified. B. The obtained k_{obs} values at various Probe 2 concentrations were used**
 241 **to provide the $(k_{inact}/K_i)_{probe}$ value.**



242


243 **Figure S19. Determination of the second-order rate constant for covalent target inactivation**
 244 **(k_{inact}/K_i) of covalent inhibitors 1-11, 13-14 and 21-37 (figure continues).**



245

246 **Figure S19. Determination of the second-order rate constant for covalent target inactivation**
 247 **(k_{inact}/K_i) of covalent inhibitors 1-11, 13-14 and 21-37.** Inhibition assays were carried out using 100 nM
 248 Ldt_{Mt2} and 10 μ M Probe 2 with 3 h incubation at rt in 50 mM HEPES, pH 7.2 with 0.01% (v/v) Triton X-
 249 100. Data points represent values of independent repeats (n=4). Average (k_{inact}/K_i)_{inhibitor} values and
 250 compound structures are given in Table S5.

251



252

253 **Figure S20. Analysis of the intrinsic thiol reactivity (k_{chem}) assay. (A)** The assay measures competition
 254 between glutathione (GSH) and test compounds for reaction with probe **2**. **(B)** Compounds **i-iii** used
 255 for validation of the k_{chem} assay. **(C)** k_{chem} of **i-iii** obtained from the fluorogenic assay with probe **2** versus
 256 the k_{chem} values reported from the fluorogenic assay with *o*-maleimide BODIPY.⁶ **(D)** GSH reacts
 257 covalently and irreversibly with probe **2** under the tested conditions. GSH (2 μM) was incubated with
 258 probe **2** (200 μM) for 16 hours in 50 mM tris, pH 7.5, prior to addition of *N*-ethylmaleimide (2 mM) and
 259 incubation of an additional 24 h. Only the mass of GSH modified with probe **2** ($[\text{M}+\text{H}]^+$ 474, $[\text{M}+\text{Na}]^+$
 260 496) was observed. **(E)** Structure and molecular mass of the anticipated product from the reaction of
 261 GSH and probe **2**.

262 **Table S11.** k_{chem} of i-iii obtained from the fluorogenic assay with probe 2 versus the k_{chem} values
263 reported from the fluorogenic assay with *o*-maleimide BODIPY.⁶

Compound	$\log(k_{\text{chem}})$ probe 2 (mean \pm SD)	$\log(k_{\text{chem}})$ <i>o</i> -maleimide BODIPY (mean \pm SD)
i	0.65 \pm 0.06	0.86 \pm 0.09
ii	0.76 \pm 0.03	1.07 \pm 0.09
iii	0.93 \pm 0.02	1.34 \pm 0.10

264

265

266 **Table S12. Inhibitory activity of selected hit compounds against *M. tuberculosis* and cytotoxicity in**
 267 **HepG2 cells.** MIC₅₀ intracellular values represent the concentration of inhibitor that inhibited *M.*
 268 *tuberculosis* (strain H37Rv) growth in THP1 cells by 50%, as obtained from extrapolation of the dose-
 269 response curve. MIC₅₀ extracellular values represent the concentration of inhibitor that inhibited *M.*
 270 *tuberculosis* (strain H37Rv) growth by 50%, as obtained from extrapolation of the dose-response curve.

	Structure	MIC ₅₀ intracellular (μM)	MIC ₅₀ extracellular (μM)	HepG2 IC ₅₀ (μM)
1		35.5 ± 4.9	>100	N.D.
5		25.7 ± 0.30	>100	2.51 ± 0.12
7		39.8 ± 0.0	>100	3.90 ± 0.88
15		7.08 ± 0.16	>100	9.55 ± 0.22
17		15.1 ± 0.70	>100	53.5 ± 6.7
18		35.5 ± 5.4	>100	42.3 ± 3.4
20		38.9 ± 1.8	>100	>100
23		12.0 ± 1.5	>100	28.8 ± 0.0

	Structure	MIC ₅₀ intracellular (μM)	MIC ₅₀ extracellular (μM)	HepG2 IC ₅₀ (μM)
30		0.98 \pm 1.2	>100	3.98 \pm 0.10
36		29.5 \pm 0.0	>100	32.7 \pm 0.38
39		28.8 \pm 0.0	>100	>100

271

272

Table S13. Data collection and refinement statistics for Ldt_{Mt2} inhibitor crystal structures.

Datasets	Ldt _{Mt2} – 2 (PDB: 8A1L)	Ldt _{Mt2} – 3 (PDB: 8A1J)	Ldt _{Mt2} – 4 (PDB: 8A1M)
Data Collection			
Beamline (Wavelength, Å)	DLS I03 (0.9763)	DLS I03 (0.9763)	DLS I03 (0.9763)
Detector	Eiger2 XE 16M	Eiger2 XE 16M	Eiger2 XE 16M
Data Processing	Xia2 dials	Xia2 3dii	Xia2 3dii
Space group	<i>P</i> 1 2 ₁ 1	<i>P</i> 1 2 ₁ 1	<i>P</i> 1 2 ₁ 1
Cell dimensions			
<i>a, b, c</i> (Å)	61.76, 94.77, 75.74	61.19, 94.02, 75.29	61.70, 95.07, 75.45
α, β, γ (°)	90.00, 92.90, 90.00	90.00, 92.61, 90.00	90.00, 92.22, 90.00
No. of molecules/ASU	2	2	2
No. reflections	38420 (1817)*	27561 (1234)*	38184 (1886)*
Resolution (Å)	61.68-2.30 (2.34-2.30)*	47.01-2.54 (2.58-2.54)*	48.66-2.30 (2.34-2.30)*
<i>R</i> _{merge} (I)	0.162 (1.331)*	0.237 (1.859)*	0.131 (1.291)*
<i>I</i> / σ <i>I</i>	9.8 (1.0)*	7.4 (1.0)*	9.6 (1.4)*
CC-1/2	1.0 (0.8)*	1.0 (0.6)*	1.0 (0.6)*
Completeness (%)	99.6 (96.1)*	97.9 (89.7)*	98.5 (98.7)*
Multiplicity	6.9 (7.2)*	6.8 (5.8)*	6.9 (6.8)*
Wilson B value (Å ²)	33.84	31.08	40.55
Refinement			
<i>R</i> _{work} / <i>R</i> _{free}	0.2146/0.2476	0.2346/0.2663	0.2179/0.2501
No. atoms	5775	5616	5782
- Enzyme	5276	5231	5319
- Ligand	76	46	81
- Water	423	339	382
Average B-factors	47.06	52.20	53.20
- Enzyme	46.99	52.46	53.17
- Ligand	55.35	58.79	66.73
- Water	46.40	47.23	50.85
RMS [§] deviations			
- Bond lengths (Å)	0.003	0.003	0.003
- Bond angles (°)	0.51	0.58	0.53

274 # ASU = asymmetric unit.

275 § RMS = root mean square.

276 *Highest resolution shell in parentheses.

Datasets	Ldt_{Mt2} – 8 (PDB: 8A1O)	Ldt_{Mt2} – 13 (PDB: 8A1N)	Ldt_{Mt2} – 15 (PDB: 8A1K)
Data Collection			
Beamline (Wavelength, Å)	DLS I03 (0.9763)	DLS I03 (0.9763)	DLS I03 (0.9763)
Detector	Eiger2 XE 16M	Eiger2 XE 16M	Eiger2 XE 16M
Data Processing	Xia2 dials	Xia2 dials	Xia2 dials
Space group	<i>P</i> 2 ₁ 2 ₁ 2	<i>P</i> 1 2 ₁ 1	<i>P</i> 1 2 ₁ 1
Cell dimensions			
<i>a, b, c</i> (Å)	76.87, 93.00, 61.40	60.93, 94.63, 75.36	60.98, 95.17, 75.62
α, β, γ (°)	90.00, 90.00, 90.00	90.00, 92.35, 90.00	90.00, 92.35, 90.00
No. of molecules/ASU	1	2	2
No. reflections	31561 (1582)*	53680 (2613)*	86822 (4298)*
Resolution (Å)	46.50-1.95 (1.98-1.95)*	75.29-2.05 (2.08-2.05)*	60.93-1.75 (1.78-1.75)*
<i>R</i> _{merge} (<i>I</i>)	0.066 (0.593)*	0.090 (0.826)*	0.063 (0.759)*
<i>I</i> / σ <i>I</i>	24.2 (3.5)*	13.2 (1.1)*	17.7 (1.0)*
CC-1/2	1.0 (0.9)*	1.0 (0.8)*	1.0 (0.8)*
Completeness (%)	96.2 (97.1)*	99.9 (97.9)*	100.0 (99.3)*
Multiplicity	12.6 (11.5)*	6.8 (6.8)*	6.6 (6.6)*
Wilson B value (Å ²)	24.43	31.68	23.14
Refinement			
	PHENIX	PHENIX	PHENIX
<i>R</i> _{work} / <i>R</i> _{free}	0.1939/0.2228	0.1954/0.2379	0.1837/0.2107
No. atoms	3166	5937	6401
- Enzyme	2696	5296	5367
- Ligand	42	42	43
- Water	428	599	991
Average B-factors	37.22	44.34	34.55
- Enzyme	35.97	44.07	32.96
- Ligand	58.19	53.53	40.01
- Water	43.07	46.05	42.92
RMS [§] deviations			
- Bond lengths (Å)	0.010	0.003	0.011
- Bond angles (°)	0.88	0.58	0.94

278 # ASU = asymmetric unit.

279 § RMS = root mean square.

280 *Highest resolution shell in parentheses.

281

Datasets	Ldt _{Mt2} – 31 (PDB: 8AHO)
Data Collection	
Beamline (Wavelength, Å)	DLS I03 (0.9763)
Detector	Eiger2 XE 16M
Data Processing	Xia2 dials
Space group	<i>P</i> 1 2 ₁ 1
Cell dimensions	
<i>a, b, c</i> (Å)	61.25, 94.26, 75.67
α, β, γ (°)	90.00, 92.69, 90.00
No. of molecules/ASU	2
No. reflections	38141 (3764)*
Resolution (Å)	48.69-2.30 (2.38-2.30)*
<i>R</i> _{merge} (I)	0.136 (0.781)*
<i>I</i> / σ <i>I</i>	8.9 (1.3)*
CC-1/2	1.0 (0.9)*
Completeness (%)	99.8 (98.4)*
Multiplicity	6.9 (6.8)*
Wilson B value (Å ²)	39.27
Refinement	PHENIX
<i>R</i> _{work} / <i>R</i> _{free}	0.2101/0.2495
No. atoms	5701
- Enzyme	5267
- Ligand	41
- Water	393
Average B-factors	45.27
- Enzyme	45.18
- Ligand	66.22
- Water	44.40
RMS [§] deviations	
- Bond lengths (Å)	0.002
- Bond angles (°)	0.54

282 # ASU = asymmetric unit.

283 [§] RMS = root mean square.

284 *Highest resolution shell in parentheses.

285

286 **Experimental details for the HTS assay optimisation process**

287 **Optimisation of reagent concentrations and reaction volume**

288 The specified volume of assay buffer (50 mM sodium phosphate pH 7.5 with 0.01% (v/v) Triton X-100)
289 was added to a black polystyrene, flat-bottomed, small volume, clear bottomed 384-well microplate
290 (Greiner Bio-One, part number 784076) using a MultiDrop Combi dispenser (ThermoFisher Scientific).
291 To this was added the specified concentrations of Ldt_{Mt2} and probe **1**.¹ The fluorescence intensity was
292 measured for the specified time using an Envision 2104 Multilabel Reader (Perkin Elmer) with
293 $\lambda_{\text{ex}}=485$ nm, $\lambda_{\text{em}}=540$ nm and a general dual mirror. All reactions were carried out in quadruplicate,
294 with no-enzyme control measurements included.

295 **DMSO tolerance assay**

296 A Ldt_{Mt2} stock solution of 600 nM (2x final concentration 300 nM) was prepared in the assay buffer
297 (50 mM sodium phosphate pH 7.5 with 0.01% (v/v) Triton X-100). A solution of probe **1** (30 μ M, 2x final
298 concentration 15 μ M) was prepared in the assay buffer. A dilution series of DMSO ranging from 33.3%
299 to 0.003% (v/v) was added to a black polystyrene, flat-bottomed, small volume, clear bottomed 384-
300 well microplate (Greiner Bio-One, part number 784076) using a HP D300 Digital Dispenser. To each
301 well was added 5 μ L of the 2x Ldt_{Mt2} stock and 5 μ L of the 2x probe **1** stock using a MultiDrop Combi
302 dispenser (ThermoFisher Scientific). The fluorescence intensity was measured every minute for
303 60 minutes using an Envision 2104 Multilabel Reader (Perkin Elmer) with $\lambda_{\text{ex}}=485$ nm, $\lambda_{\text{em}}=540$ nm and
304 a general dual mirror. All reactions were carried out in quadruplicate, with no-enzyme control and no
305 DMSO control measurements included.

306 **Detergent optimisation**

307 An Ldt_{Mt2} stock solution of 600 nM (2x final concentration 300 nM) was prepared in the assay buffer
308 (50 mM sodium phosphate pH 7.5). Stock solutions of 20 x critical micelle concentration (CMC) of the
309 detergents Triton X-100, Triton X-114, Tween-20 (Thermo Scientific), Tween-80, MEGA-8, CHAPS, BRIJ-
310 35, IPEGAL-630, n-dodecyl- β -D-maltose, BSA and dBSA (prepared by incubation of BSA for 15 minutes
311 at 80 °C, followed by 2 hours at room temperature and stored at -20 °C) were prepared. Using a HP
312 D300 Digital Dispenser 11 concentrations of 1/2 step dilutions were added to a black polystyrene, flat-
313 bottomed, small volume, clear bottomed 384-well microplate (Greiner Bio-One, part number 784076).
314 To each well was added 5 μ L of the 2x Ldt_{Mt2} stock and 5 μ L of the 2x probe **1** stock solution using a
315 MultiDrop Combi dispenser (ThermoFisher Scientific). The fluorescence intensity was measured every
316 minute for 60 minutes using an Envision 2104 Multilabel Reader (Perkin Elmer) with $\lambda_{\text{ex}}=485$ nm,
317 $\lambda_{\text{em}}=540$ nm and a general dual mirror. All reactions were carried out in quadruplicate, with no-enzyme
318 control and no detergent control measurements included. Maximum tolerated concentrations were
319 calculated by analysing the resulting slopes using Microsoft Excel. Buffers of the detergents in
320 maximum tolerated concentrations, or 1 x CMC where no interference was observed, in 50 mM sodium
321 phosphate pH 7.5 were prepared, omitting BRIJ-35, IPEGAL-630, BSA and dBSA due to interference at
322 all concentrations. With each buffer, a Ldt_{Mt2} stock of 600 nM (2x final concentration 300 nM) and a
323 probe **1** stock solution of 30 μ M (2x final concentration 15 μ M) was prepared. To each well was added
324 5 μ L of the 2x Ldt_{Mt2} stock solution and 5 μ L of the 2x probe **1** stock solution using a MultiDrop Combi
325 dispenser (ThermoFisher Scientific). The fluorescence intensity was measured every minute for 60
326 minutes using an Envision 2104 Multilabel Reader (Perkin Elmer) with $\lambda_{\text{ex}}=485$ nm, $\lambda_{\text{em}}=540$ nm and a

327 general dual mirror. All reactions were carried out in quadruplicate, with no-enzyme control
328 measurements included.

329 **Plate reader protocol optimisation**

330 A stock solution of Ldt_{Mt2} of 600 nM (2x final concentration 300 nM) was prepared in the assay buffer
331 (50 mM sodium phosphate pH 7.5 with 0.007% (v/v) Tween-20). A stock solution of probe **1** of 30 µM
332 (2x final concentration 15 µM) was prepared in the assay buffer. To each well was added 5 µL of the
333 2x Ldt_{Mt2} stock solution and 5 µL of the 2x probe **1** stock solution using a MultiDrop Combi dispenser
334 (ThermoFisher Scientific). The fluorescence intensity was measured every minute for 60 minutes using
335 a Envision 2104 Multilabel Reader (Perkin Elmer) with λ_{ex}=485 nm, λ_{em}=540 nm and a FITC mirror. The
336 plate reader protocol was optimised for the coordinates of the corners, measurement height and gain.

337 **Stability of stock solution concentrations**

338 A stock solution of Ldt_{Mt2} of 600 nM (2x final concentration 300 nM) was prepared in the assay buffer
339 (50 mM sodium phosphate pH 7.5 with 0.007% (v/v) Tween-20). A stock solution of probe **1** of 30 µM
340 (2x final concentration 15 µM) was prepared in the assay buffer. The stock solutions were kept on ice
341 for 7 hours, after which time 5 µL of the 2x Ldt_{Mt2} solution and 5 µL of the 2x probe **1** solution were
342 added to a black polystyrene, flat-bottomed, small volume, clear bottomed 384-well microplate
343 (Greiner Bio-One, part number 784076) using a MultiDrop Combi dispenser (ThermoFisher Scientific).
344 The fluorescence intensity was measured every minute for 60 minutes using an Envision 2104
345 Multilabel Reader (Perkin Elmer) with λ_{ex}=485 nm, λ_{em}=540 nm and a FITC mirror.

346 **Full plate analysis**

347 A stock solution of Ldt_{Mt2} of 600 nM (2x final concentration 300 nM) was prepared in the assay buffer
348 (50 mM sodium phosphate pH 7.5 with 0.007% (v/v) Tween-20). A stock solution of probe **1** of 30 µM
349 (2x final concentration 15 µM) was prepared in the assay buffer. To a black polystyrene, flat-bottomed,
350 small volume, clear bottomed 384-well microplate (Greiner Bio-One, part number 784076) was added
351 100 nL of DMSO to all wells using a HP D300 Digital Dispenser. To this was added 5 µL of the 2x Ldt_{Mt2}
352 stock solution and 5 µL of the 2x probe **1** stock solution using a MultiDrop Combi dispenser
353 (ThermoFisher Scientific). The fluorescence intensity was measured every 5 minutes for 10 hours using
354 a Envision 2104 Multilabel Reader (Perkin Elmer) with λ_{ex}=485 nm, λ_{em}=540 nm and a FITC mirror.

355 **Dose-response analysis with tool compounds**

356 Inhibitor solutions (in DMSO, concentrations ranging from 100 µM to 1.69 nM) were added to a black
357 polystyrene, flat-bottomed, small volume, clear bottomed 384-well microplate (Greiner Bio-One, part
358 number 784076), with DMSO concentrations normalised to 1% (100 nL) in each well using a Hewlett-
359 Packard D300 Digital Dispenser.

360 The so obtained plates were stored at -20 °C until use. A stock solution of Ldt_{Mt2} of 600 nM (2x final
361 concentration 300 nM) was prepared in the assay buffer (50 mM sodium phosphate pH 7.5 with
362 0.007% (v/v) Tween-20). A stock solution of probe **1** of 30 µM (2x final concentration 15 µM) was
363 prepared in the assay buffer. To the inhibitor plates was added 5 µL of the 2x Ldt_{Mt2} stock solution using
364 a MultiDrop Combi dispenser (ThermoFisher Scientific). The resulting solution was incubated for 10
365 minutes at room temperature without shaking. 5 µL of the 2x probe **1** stock solution was then added
366 using a MultiDrop Combi dispenser (ThermoFisher Scientific). The plate was incubated for another 10

367 minutes at room temperature. The fluorescence intensity was then measured 5 minute intervals for
368 50 minutes using an Envision 2104 Multilabel Reader (Perkin Elmer) with $\lambda_{ex}=485$ nm, $\lambda_{em}=540$ nm and
369 a FITC mirror. The slope was calculated using linear regression analysis. The normalised response was
370 calculated using the following formula: Normalized response = $100 * ((\text{slope} - \text{slope control 2}) / (\text{slope}$
371 $\text{control 1} - \text{slope control 2}))$. The dose-response analysis was performed in Prism (GraphPad), using the
372 log(inhibitor) versus normalized response- variable slope function.

373

374 **References**

- 375 1. de Munnik, M.; Lohans, C. T.; Langley, G. W.; Bon, C.; Brem, J.; Schofield, C. J., A Fluorescence-
376 Based Assay for Screening β -Lactams Targeting the Mycobacterium tuberculosis Transpeptidase
377 LdtMt2. *ChemBioChem* **2020**, *21*, 368-372.
- 378 2. Van Berkel, S. S.; Brem, J.; Rydzik, A. M.; Salimraj, R.; Cain, R.; Verma, A.; Owens, R. J.;
379 Fishwick, C. W. G.; Spencer, J.; Schofield, C. J., Assay Platform for Clinically Relevant Metallo- β -
380 lactamases. *J. Med. Chem.* **2013**, *56*, 6945-6953.
- 381 3. de Munnik, M.; Lohans, C. T.; Lang, P. A.; Langley, G. W.; Malla, T. R.; Tumber, A.; Schofield,
382 C. J.; Brem, J., Targeting the Mycobacterium tuberculosis transpeptidase LdtMt2 with cysteine-reactive
383 inhibitors including ebselen. *Chem. Commun.* **2019**, *55*, 10214-10217.
- 384 4. Schörghener, J.; Waser, M., New strategies and applications using electrophilic cyanide-
385 transfer reagents under transition metal-free conditions. *Org. Chem. Front.* **2016**, *3* (11), 1535-1540.
- 386 5. Charpentier, J.; Früh, N.; Togni, A., Electrophilic Trifluoromethylation by Use of Hypervalent
387 Iodine Reagents. *Chem. Rev.* **2015**, *115* (2), 650-682.
- 388 6. Sameshima, T.; Miyahisa, I.; Yamasaki, S.; Gotou, M.; Kobayashi, T.; Sakamoto, J., High-
389 Throughput Quantitative Intrinsic Thiol Reactivity Evaluation Using a Fluorescence-Based Competitive
390 Endpoint Assay. *Adv. Sci. Drug Disc.* **2017**, *22*, 1168-1174.

391